<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494572</url>
  </required_header>
  <id_info>
    <org_study_id>PPRU 10856</org_study_id>
    <nct_id>NCT00494572</nct_id>
  </id_info>
  <brief_title>Montelukast With Status Asthmaticus, Ages 6-18</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Montelukast in Children, Ages 6 Through 18 Years Old, With Status Asthmaticus Unresponsive to Conventional Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Pharmacology Research Units Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if montelukast, in addition to standard treatment&#xD;
      is helpful in treating patients ages 6-18 who are in the hospital because of status&#xD;
      asthmaticus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study of montelukast efficacy in addition to standard treatment of&#xD;
      status asthmaticus in children who are in the PICU. The study will be stratified in 2 groups:&#xD;
      children 6-12 years of age and adolescents 13-18 years of age. Children who meet eligibility&#xD;
      requirements will be randomized to receive a rapid-dissolving oral dose of montelukast or&#xD;
      placebo. Participants will be given a physical exam, have FEV1 measurements and clinical&#xD;
      asthma scores recorded pre- and post- completion of a nebulized albuterol treatment of 0.1&#xD;
      mg/kg/dose (min 2.5 mg/dose). Blood samples for PK analysis will be collected prior to study&#xD;
      drug administration and at predetermined time intervals to determine the plasma level of&#xD;
      montelukast. In addition, a blood sample will be obtained for genetic study of polymorphisms&#xD;
      of CYP3A4, CYP3A5, and CYP2C9.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate effectiveness of Montelukast as adjunctive therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate the first dose pharmacokinetic parameter of Montelukast</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Status Asthmaticus</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sterile Water</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sterile water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg rapid dissolving granules in sterile water orally once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>10 mg rapid dissolving granule in sterile water orally once</description>
    <arm_group_label>Montelukast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sterile water</intervention_name>
    <description>sterile water</description>
    <arm_group_label>Sterile Water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant's parent/legal guardian must give written informed consent and written&#xD;
             assent must be obtained form the subject prior to study participation.&#xD;
&#xD;
               1. Obtain consent of the parent/legal guardian using a signed consent form;&#xD;
&#xD;
               2. Obtain assent form minors between the ages of 7-13 using a signed assent form;&#xD;
&#xD;
               3. Obtain assent from minors between the ages of 14-17 by having the subject sign&#xD;
                  the consent formed signed the parent / legal guardian (Or based on the assessment&#xD;
                  by the Primary Investigator that the patient is unable to comprehend the study as&#xD;
                  written in the consent form document, the patient may document assent by signing&#xD;
                  the assent form).&#xD;
&#xD;
          -  Participant, male or female, must be 6 to 18 years of age.&#xD;
&#xD;
          -  Participant must have a history of reactive airway disease (RAD) or asthma and must&#xD;
             currently be admitted for an acute exacerbation of RAD or asthma.&#xD;
&#xD;
          -  Primary physician must believe that patient would benefit from improved&#xD;
             bronchodilation and improvement in clinical asthma severity score.&#xD;
&#xD;
          -  Participant must have received standard therapy for status asthmaticus:&#xD;
&#xD;
               1. Oxygen as needed&#xD;
&#xD;
               2. &gt;3 nebulized albuterol treatments of at least 2.5mg/dose&#xD;
&#xD;
               3. Methylprednisolone or prednisone loading dose of 2mg/kg&#xD;
&#xD;
               4. Ongoing methylprednisolone therapy @ 0.5mg/kg every 6 hours&#xD;
&#xD;
          -  Participant must have received steroids at least 6 hours prior to their inclusion, and&#xD;
             must still require nebulized albuterol at least every 2 hours, as determined by PICU&#xD;
             team in accordance with the PICU standard for evaluating and treating patients with&#xD;
             RAD or asthma exacerbations.&#xD;
&#xD;
          -  Participant must have an indwelling catheter in place from which to obtain blood&#xD;
             specimens. Catheter may be peripheral or central, arterial or venous.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to montelukast&#xD;
&#xD;
          -  Chronic lung disease other than RAD or asthma&#xD;
&#xD;
          -  Known renal disease&#xD;
&#xD;
          -  Known hepatic disease&#xD;
&#xD;
          -  Cardiac or pulmonary congenital anomalies&#xD;
&#xD;
          -  Known immunologic disorders other than allergy and atopy&#xD;
&#xD;
          -  Other explanations for respiratory distress&#xD;
&#xD;
          -  Use of leukotriene modifiers within 2 weeks of the acute presentation&#xD;
&#xD;
          -  Pregnant females&#xD;
&#xD;
          -  Intubated patients&#xD;
&#xD;
          -  Inability to participate in portable spirometry for FEV1 measurement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Blumer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PPRU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eloise Lemon, RN</last_name>
      <phone>216-844-3681</phone>
      <email>eloise.lemon@uhhs.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Blumer, Ph.D., M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2007</study_first_posted>
  <last_update_submitted>December 15, 2008</last_update_submitted>
  <last_update_submitted_qc>December 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jeffrey L. Blumer, Ph.D., M.D.</name_title>
    <organization>University Hospitals Case Medical Center</organization>
  </responsible_party>
  <keyword>Montelukast</keyword>
  <keyword>Albuterol</keyword>
  <keyword>Status Asthmaticus</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Asthmaticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

